ClinicaliQ Trial Snapshot
- Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment — Recruiting • Phase III • Oncology • NCT07160686.
- What is being tested: Apixaban (an oral anticoagulant) versus standard care to evaluate its effectiveness in preventing venous thromboembolism (VTE) in ambulatory patients with lung cancer receiving systemic anticancer treatment such as chemotherapy.
- Patient eligibility overview: Ambulatory (non-hospitalised) patients diagnosed with lung cancer who are commencing or currently undergoing systemic anticancer therapy, without established contraindications to anticoagulation.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The aim of this trial is to find out if a tablet called apixaban can reduce blood clots in people with lung cancer having chemotherapy or similar treatments. Apixaban is a type of oral anticoagulant ("blood thinner") that makes the blood less sticky to prevent blood clots forming. The trial is trying to find out if apixaban it can reduce blood clots in people with lung cancer. Participants will receive the following treatment: • Apixaban or placebo, 2.5mg taken by mouth twice a day for 6 months. This treatment will…
Eligibility Snapshot
- * Age ≥ 16 years * Newly diagnosed locally advanced or metastatic primary lung cancer (histologically/ cytologically confirmed) or disease progression after complete or partial remission commencing a new course of SACT alone or as CRT * Ambulatory (receiving outpatient SACT)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.